Gilead To Buy 49.9% Stake In Latham-Led Drug Co. For $275M
Biopharmaceutical giant Gilead said Tuesday that it has agreed to purchase a 49.9% stake in a Latham & Watkins-advised cancer treatment company for $275 million, with the option to buy the...To view the full article, register now.
Already a subscriber? Click here to view full article